Cargando…
miRNA Regulation Network Analysis in Qianliening Capsule Treatment of Benign Prostatic Hyperplasia
Objective. The objective of this study was to evaluate the molecular mechanism by which Qianliening capsule (QC) treats benign prostatic hyperplasia (BPH). Methods. Benign prostatic hyperplasia epithelial cell line BPH-1 was treated with 0, 1.25, 2.5, and 5 mg/mL QC for 48 h, respectively. Evaluatio...
Autores principales: | Liu, Liya, Wan, Yun, Shen, Aling, Zhao, Jinyan, Lin, Jiumao, Zhong, Xiaoyong, Zhang, Yuchen, Hong, Zhenfeng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4534592/ https://www.ncbi.nlm.nih.gov/pubmed/26294924 http://dx.doi.org/10.1155/2015/365484 |
Ejemplares similares
-
Anti-proliferative effects of qianliening capsules on prostatic hyperplasia in vitro and in vivo
por: ZHONG, XIAOYONG, et al.
Publicado: (2015) -
Qianliening capsule treats benign prostatic hyperplasia via suppression of the EGF/STAT3 signaling pathway
por: LIN, JIUMAO, et al.
Publicado: (2013) -
Qianliening capsule inhibits benign prostatic hyperplasia angiogenesis via the HIF-1α signaling pathway
por: LIN, JIUMAO, et al.
Publicado: (2014) -
Circulating miRNAs as Biomarkers for Prostate Cancer Diagnosis in Subjects with Benign Prostatic Hyperplasia
por: Jin, Wei, et al.
Publicado: (2020) -
Determination of miRNA expression profile in patients with prostate cancer and benign prostate hyperplasia
por: SANCER, Okan, et al.
Publicado: (2022)